MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

CytomX Therapeutics Inc

Fermé

SecteurSoins de santé

2.36 -5.22

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.36

Max

2.44

Chiffres clés

By Trading Economics

Revenu

4.6M

24M

Ventes

13M

51M

P/E

Moyenne du Secteur

4.729

40.527

BPA

0.27

Marge bénéficiaire

46.203

Employés

119

EBITDA

4.9M

23M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+80% upside

Dividendes

By Dow Jones

Prochains Résultats

7 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

186M

358M

Ouverture précédente

7.58

Clôture précédente

2.36

Sentiment de l'Actualité

By Acuity

50%

50%

143 / 375 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

CytomX Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

7 juil. 2025, 15:29 UTC

Principaux Mouvements du Marché

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7 juil. 2025, 23:44 UTC

Market Talk

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7 juil. 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 juil. 2025, 23:41 UTC

Market Talk

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7 juil. 2025, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

7 juil. 2025, 23:19 UTC

Market Talk

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7 juil. 2025, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

7 juil. 2025, 22:20 UTC

Market Talk

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7 juil. 2025, 21:34 UTC

Acquisitions, Fusions, Rachats

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 juil. 2025, 20:45 UTC

Acquisitions, Fusions, Rachats

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 juil. 2025, 20:16 UTC

Market Talk

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7 juil. 2025, 19:37 UTC

Market Talk

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7 juil. 2025, 19:12 UTC

Market Talk

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7 juil. 2025, 18:33 UTC

Market Talk

Gold Flat as Investors Assess Market Direction -- Market Talk

7 juil. 2025, 18:27 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 juil. 2025, 16:53 UTC

Résultats

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7 juil. 2025, 16:30 UTC

Market Talk

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 juil. 2025, 16:05 UTC

Acquisitions, Fusions, Rachats

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 juil. 2025, 15:41 UTC

Market Talk

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7 juil. 2025, 15:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 juil. 2025, 15:40 UTC

Market Talk

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7 juil. 2025, 15:30 UTC

Market Talk

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7 juil. 2025, 15:18 UTC

Market Talk

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7 juil. 2025, 15:14 UTC

Acquisitions, Fusions, Rachats

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7 juil. 2025, 15:00 UTC

Acquisitions, Fusions, Rachats

GSK Completes Acquisition of Efimosfermin

7 juil. 2025, 14:52 UTC

Market Talk

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7 juil. 2025, 14:51 UTC

Market Talk

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7 juil. 2025, 14:45 UTC

Market Talk

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Comparaison

Variation de prix

CytomX Therapeutics Inc prévision

Objectif de Prix

By TipRanks

80% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  80%

Haut 5 USD

Bas 3.5 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.7658 / N/ASupport & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Very Strong Bullish Evidence

Long Terme

Weak Bullish Evidence

Sentiment

By Acuity

143 / 375Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.